Bill > SCR8

This joint resolution requests the Hawaii State Auditor to conduct a comprehensive assessment of the proposed mandated health insurance coverage for intravenous ketamine therapy to treat depression, as outlined in Senate Bill 967 for the 2025 legislative session. Specifically, the resolution asks the Auditor to evaluate both the social and financial implications of requiring insurance providers to cover a percentage of the costs for this treatment, which has been identified in medical literature as a potential effective option for treatment-resistant depression. The Auditor is asked to examine various potential coverage percentages and to submit a detailed report with findings and recommendations to the Legislature at least 20 days before the 2026 Regular Session. This request is made in accordance with Hawaii Revised Statutes section 23-51, which requires a thorough analysis of proposed health insurance mandates before they can be considered for legislative approval. The resolution reflects the state's commitment to protecting and improving residents' health, particularly for those suffering from mental health conditions, by carefully examining the potential impacts of expanding insurance coverage for innovative treatment options.

Budget and Finance, Health and Social Services

https://www.capitol.hawaii.gov/session/measure_indiv.aspx?billtype=SCR&billnumber=8&year=2025